1-(4-Chlorophenyl)-N-(3-phenylpropyl)cyclopropanecarboxamide | 872421-40-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-Chlorophenyl)-N-(3-phenylpropyl)cyclopropanecarboxamide
• 英文别名: 1-(4-chlorophenyl)-N-(3-phenylpropyl)cyclopropane-1-carboxamide
• CAS: 872421-40-4
• 化学式: C₁₉H₂₀ClNO
• 分子量: 313.827
• InChiKey: UUHABTGKPQWPRM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(4-Chlorophenyl)-N-(3-phenylpropyl)cyclopropanecarboxamide 在 五氯化磷 、 叠氮基三甲基硅烷 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 5-[1-(4-Chloro-phenyl)-cyclopropyl]-1-(3-phenyl-propyl)-1H-tetrazole
  参考文献：
  名称：

  Discovery and in vitro/in vivo studies of tetrazole derivatives as Kv1.5 blockers

  摘要：

  A novel class of tetrazole-derived Kv1.5 blockers is disclosed. In in vitro studies, several compounds had IC(50)s ranging from 180 to 550 nM. In vivo studies indicated that compounds 2f and 2j increased right atrial ERP about 40% without affecting ventricular ERP. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.09.021
• 作为产物：
  描述：

  1-(4-氯苯基)-1-环丙烷羧酸 在 氯化亚砜 作用下， 以 四氢呋喃 为溶剂， 反应 5.0h， 生成 1-(4-Chlorophenyl)-N-(3-phenylpropyl)cyclopropanecarboxamide
  参考文献：
  名称：

  Discovery and in vitro/in vivo studies of tetrazole derivatives as Kv1.5 blockers

  摘要：

  A novel class of tetrazole-derived Kv1.5 blockers is disclosed. In in vitro studies, several compounds had IC(50)s ranging from 180 to 550 nM. In vivo studies indicated that compounds 2f and 2j increased right atrial ERP about 40% without affecting ventricular ERP. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.09.021

文献信息

• Amido compounds and their use as pharmaceuticals
  申请人：Yao Wenqing

  公开号：US20050288338A1

  公开（公告）日：2005-12-29

  The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor MR, and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.

  本发明涉及11-β羟基类固醇脱氢酶类型1的抑制剂，矿物皮质激素受体MR的拮抗剂以及其药物组成物。本发明的化合物可用于治疗与11-β羟基类固醇脱氢酶类型1的表达或活性以及与醛固酮过度相关的各种疾病。
• AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS
  申请人：INCYTE CORPORATION

  公开号：EP1773780A2

  公开（公告）日：2007-04-18
• EP1773780A4
  申请人：——

  公开号：EP1773780A4

  公开（公告）日：2008-01-09
• [EN] AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS<br/>[FR] COMPOSES AMIDO ET UTILISATIONS DE CES DERNIERS EN TANT QUE PRODUITS PHARMACEUTIQUES
  申请人：INCYTE CORP

  公开号：WO2006012227A2

  公开（公告）日：2006-02-02

  The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor MR, and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
• Discovery and in vitro/in vivo studies of tetrazole derivatives as Kv1.5 blockers
  作者：Shengde Wu、Andrew Fluxe、Jim Sheffer、John M. Janusz、Benjamin E. Blass、Ron White、Chris Jackson、Richard Hedges、Michael Murawsky、Bin Fang、Gina M. Fadayel、Michelle Hare、Laurent Djandjighian

  DOI：10.1016/j.bmcl.2006.09.021

  日期：2006.12

  A novel class of tetrazole-derived Kv1.5 blockers is disclosed. In in vitro studies, several compounds had IC(50)s ranging from 180 to 550 nM. In vivo studies indicated that compounds 2f and 2j increased right atrial ERP about 40% without affecting ventricular ERP. (c) 2006 Elsevier Ltd. All rights reserved.